Volume : 12, Issue : 11, November – 2025
Title:
HERBAL DRUG USED IN CARDIOVASCULAR DISEASE
Authors :
Shashank S. kakade*, Aditi V. Tikait, Dr. Swati P Deshmukh
Abstract :
Cardiovascular diseases (CVDs) remain a primary cause of death around the world, necessitating the development of innovative and safer therapeutic approaches. Herbal medications such as Hawthorn (Crataegus spp.) and Arjuna (Terminalia arjuna) have demonstrated outstanding cardio protective, antioxidant, hypolipidemic, and antihypertensive effects. The combination of herbal therapy and conventional medicine provides a comprehensive approach to the treatment and prevention of cardiovascular problems. However, standardization, dosage optimization, and clinical validation are required to ensure their safety and efficacy.
When used properly and supported by scientific study, they can make a substantial contribution to worldwide heart health while also effectively complementing modern pharmaceutical treatments. Herbal products can also be unsafe due to contamination with heavy metals or pesticides, depending on where the plants are grown. Even though there are many challenges, not many herbal products are completely unsafe to use with regular medicines when taken in normal amounts.
Keywords: Cardiovascular Disease, Risk Factor, Role of Herbal Drug, Medicinal Plant Use, Classification, Dose Administration.
Cite This Article:
Please cite this article in press Shashank S Kakade et al., Herbal Drug Used In Cardiovascular Disease, Indo Am. J. P. Sci, 2025; 12(11).
REFERENCES:
1. Ray S, Saini MK. Cure and prevention of cardiovascular diseases: herbs for heart. Clinical Phytoscience. 2021 Jul 14;7(1):64.
2. Cojocaru-Toma M, Ciobanu N, Ciobanu C, Benea A, Guranda D, Ohindovschi A, Pislari O. Produse vegetale și plante medicinale cu acțiune diuretică (Herbal products and medicinal plants with diuretic action). Rev Farm Mold. 2021;47:60-64.
3. Gouws C, Hamman JH. What are the dangers of drug interactions with herbal medicines? Expert Opin Drug Metab Toxicol. 2020;16(2):165–167.
4. Xiong X, Borrelli F, de Sá Ferreira A, Ashfaq T, Feng B. Herbal medicines for cardiovascular diseases. Evidence-based complementary and alternative medicine:
eCAM. 2014 Nov 25;2014:809741.
5. Ojha S, Al Taee H, Goyal S, Mahajan UB, Patil CR, Arya DS, Rajesh M. Cardioprotective potentials of plant‐derived small molecules against doxorubicin associated cardiotoxicity. Oxidative medicine and cellular longevity. 2016;2016(1):5724973.
6. Mohanty I, Gupta SK, Arya DS. Antiapoptotic and cardioprotective effects of a herbal combination in rats with experimental myocardial infarction. Int J Integr Biol. 2007 Dec;1(3):178-88.
7. Nyulas KI, Simon-Szabó Z, Pál S, Fodor MA, Dénes L, Cseh MJ, Barabás-Hajdu E, Csipor B, Szakács J, Preg Z, Germán-Salló M. Cardiovascular effects of herbal products and their interaction with antihypertensive drugs—Comprehensive review. International Journal of Molecular Sciences. 2024 Jun 9;25(12):6388.
8. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The lancet. 2004 Sep 11;364(9438):937-52.
9. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 2019 Mar 5;139(10):e56-28.
10. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation.
1998;97(18):1837–47.
11. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, Daniels S, Nichol G, Tomaselli GF, Arnett DK. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic Impact Goal through 2020 and beyond. Circulation. 2010 Feb 2;121(4):586-613.
12. Rahman K. Garlic and cardiovascular disease: a review. J Nutr. 2007;136(3 Suppl):736S–40S.
13. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: Part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104(22):2746–53. Doi:10.1161/hc4601.099487.
14. Singhal P, Singh R, Sharma A, Chauhan T, Maheshwari A. Hypertension and its Pathophysiology: Exploring the Role of Herbal Remedies. Asian Pacific Journal of Nursing and Health Sciences. 2024;7(2):8-14.
15. Smith J, Brown P, Jones T. The efficacy of Hawthorn extract in cardiovascular disease treatment: a comprehensive review. J Cardiovasc Med. 2023;12(5):101–10.
16. Chen X, Li Y, Zhang H, Wang J, Liu Q. Insights into phylogeny, taxonomy, origins and evolution of Crataegus and Mespilus, based on comparative chloroplast genome analysis. Genes. 2025;16(2):204.
17. Christensen KI. Revision of Crataegus (Rosaceae) in Europe and Western Asia. Nord J Bot. 1992;12(6):657–666.
18. Meng J, Wang Y, Song H, Dong W, Dong N. Insights into Phylogeny, Taxonomy, Origins and Evolution of Crataegus and Mespilus, Based on Comparative Chloroplast Genome Analysis. Genes. 2025 Feb 7;16(2):204.
19. .Dwivedi S, Jauhari R. Beneficial effects of Terminalia arjuna in coronary artery disease. Indian Heart J. 1997;49:507-510.
20. Gauthaman K, Maulik M, Ghosh S, Das DK. Protective effects of Terminalia arjuna against oxidative stress in isolated rat heart. J Ethnopharmacol. 2001;75:1–9.
21. Hawthorn: Usefulness and Safety.” National Center for Complementary and Integrative Health (NCCIH)
22. “Dosage and Standardization” in American Family Physician article (2010) summarizing 160-1,800 mg/day in 2-3 divided doses.
23. Dwivedi S. Terminalia arjuna Wight & Arn. -a useful drug for cardiovascular disorders.
J Ethnopharmacol. 2007;114(2):114-129.
24. Holubarsch CJ, Colucci WS, Meinertz T, Gaus W, Tendera M. Survival and prognosis: pilot study of Crataegus extract WS 1442 in patients with congestive heart failure. Am Heart J. 2001;142(5):910–915.
25. . Pittler MH, Schmidt K, Ernst E. Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials. Am J Med. 2003;114(8):665–674.
26. Walker AF, Marakis G, Morris AP, Robinson PA. Promising hypotensive effect of hawthorn extract: a randomized double‐blind pilot study of mild, essential hypertension. Phytotherapy Research. 2002 Feb;16(1):48-54.
27. World Health Organization. WHO monographs on selected medicinal plants. World Health Organization; 1999.
28. Lu M, Chen C, Li J, Wang Y, Chen Y, Zhang H, Cardioprotective effects and mechanisms of natural polyphenols: insights from experimental and clinical studies. Food Funct. 2023;14:5870–5890.
29. WHO Monographs on Selected Medicinal Plants, Vol. 2, 2004. EMA Herbal Monograph, 2016.
30. Chrubasik C, Li G, Chrubasik S. The clinical effectiveness of Crataegus preparations in cardiovascular conditions. Phytomedicine. 2008;15(9):744–752.
31. Veveris M, Koch E, Chatterjee SS. Crataegus special extract WS 1442 improves cardiac function and reduces infarct size in a rat model of myocardial ischemia and reperfusion. Planta Med. 2004;70(10):907–914.
32. Jain S, Yadav PP, Gill V, Vasudeva N, Singla N. Terminalia arjuna a sacred medicinal plant: phytochemical and pharmacological profile. Phytochemistry Reviews. 2009 Jun;8(2):491-502.
33. Chopra RN, Ghosh S. Terminalia arjuna: its chemistry, pharmacology and therapeutic action. The Indian Medical Gazette. 1929 Feb;64(2):70.
34. Varghese A, Savai J, Pandita N, Gaud R. In vitro modulatory effects of Terminalia arjuna, arjunic acid, arjunetin and arjungenin on CYP3A4, CYP2D6 and CYP2C9 enzyme activity in human liver microsomes. Toxicology Reports. 2015 Jan 1;2:806-16.
35. Dwivedi S. Terminalia arjuna Wight & Arn.—a useful drug for cardiovascular disorders. Journal of ethnopharmacology. 2007 Nov 1;114(2):114-29.
36. Jaiswal YS, Liang Z, Ho A, Chen H, Zhao ZZ. A comparative study on the phytochemical and pharmacological profiles of Tinospora cordifolia and Tinospora sinensis. Front Pharmacol. 2022;13:878290.
37. Dwivedi S. Terminalia arjuna Wight & Arn.—a useful drug for cardiovascular disorders. Journal of ethnopharmacology. 2007 Nov 1;114(2):114-29.
38. Bharani A, Ganguly A, Bhargava KD. Salutary effect of Terminalia arjuna in patients with severe refractory heart failure. International Journal of Cardiology. 1995 May 1;49(3):191-199.
39. Dwivedi S, Jauhari R. Beneficial effects of Terminalia arjuna in coronary artery disease. Indian Heart Journal. 1997 Sep 1;49(5):507-10.
40. Sharma PC, Yelne MB, Dennis TJ, Joshi A. Database on medicinal plants used in Ayurveda. New Delhi: CCRAS; 2005.
41. Ojha SK, Nandave M, Arora S, Narang R, Dinda AK, Arya DS. Cardioprotective potential of Ocimum sanctum in isoproterenol induced myocardial infarction in rats. J Ethnopharmacol. 2008;118(3):416–422.